New agent offers image of liver lesions

Article

This is the first organ-specific magnetic resonance imaging contrast agent approved in this country in more than a decade.

Liver lesions may be easier to detect now that the Food & Drug Administration has approved a new imaging agent. It's Bayer HealthCare Pharmaceuticals' Eovist (gadoxetate disodium) Injection, a gadolinium-based contrast agent, for intravenous use among patients with known or suspected focal liver disease. According to the Wayne, N.J., firm, Eovist is the first organ-specific magnetic resonance imaging contrast agent approved in this country in more than a decade.

Recent Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.